Amedisys — Q2 2017 Earnings Presentation
16 slides from Amedisys's earnings presentation, Jul 26, 2017
Slide 1: Amedisys Second Quarter 2017 Earnings Call Supplemental Slides
Amedisys Second Quarter 2017 Earnings Call Supplemental Slides July 27, 2017 Exhibit 99.2
Slide 2: Forward-looking statements
This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cau
Slide 3: Our Key Areas of Focus
Our Key Areas of Focus Strategic areas of focus for the second half of 2017 and beyond Home Health: HCHB disruption in the rear view mirror. BD FTE ramp up will drive 3Q total episodic growth of 2-3% and 4Q total episodic growth of 4-6% Hospice: Continued growth at high single / low double digit pac
Slide 4: Highlights and Summary Financial Results (Adjusted): 2Q 2017
Highlights and Summary Financial Results (Adjusted): 2Q 2017(1) Hospice (+11% same store admissions) and Personal Care (+53% billable hours) continue their strong growth. Same store Home Health episodic admissions down slightly (-1%). Cost containment initiatives performing very well driving 2Q EBIT
Slide 5: Home Health and Hospice Segment (Adjusted) – 2Q 2017
Home Health and Hospice Segment (Adjusted) – 2Q 2017(1) Overall same store episodic admits (-1%) driven by decline in Medicare same store admissions (-4%) offset by non-Medicare episodic admits (+25%) Expected total episodic admissions growth in 3Q: 2-3% CPV increase due to health care costs Home He
Slide 6: General & Administrative Expenses – Adjusted
General & Administrative Expenses – Adjusted (1,2) Notes: Year over year total G&A as a percentage of revenue decreased 230 basis points Home health segment G&A: 70 bps y/y decrease as % of revenue Hospice segment G&A: 170 bps decrease y/y as % of revenue Personal Care segment G&A: 370 bps decrease
Slide 7: Status of Ongoing Initiatives
Status Category Update Ongoing Initiative STARS / Quality Amedisys maintains above a 4-Star average (4.13) in the July 2017 HHC preview with 82% of providers at 4+ Stars Clinical Standardization Create innovative industry-leading, clinical programs and define, develop and implement standardized care
Slide 8: Clinical Distinction: Improvements in STARS
Clinical Distinction: Improvements in STARS 9th consecutive quarter of QPC STAR score improvement; 82% of providers at 4 stars or better. Additional focus now on readmissions improvement Metric Jan 17 Release Apr 17 Release Jul 17 Release Quality of Patient Care 3.91 4.03 4.13 Entities at 4+ Stars 6
Slide 9: BD FTE hiring progress and vacancy rate
Our original goal was to hire and additional 50 BD FTE’s by 2H’17. As of 7/19, we have 741 BD FTEs (750 projected July month end) and have lowered our vacancy rate to ~5% (below our target). Our new goal is to reach 775 BD FTE’s by 4Q’17 On Target to Reach 750 BD FTEs by End of July End of July 2017
Slide 10: Cost per visit components
Components 2Q’16 1Q’17 2Q’17 YoY Variance Detail Mitigation Plan Salaries $60.28 $61.48 $60.34 $0.06 $0.06 driven by planned salary increases Staffing mix optimization, productivity and scheduling improvement initiatives in place helped us overcome planned salary increases Contractors $2.87 $2.35 $2
Slide 11: Driving Top Line Growth: Metrics Across Business Segments
Driving Top Line Growth: Metrics Across Business Segments Solid growth in hospice and personal care; Medicare revenue percentage decrease due to reimbursement cut and significant growth in private episodic 234 Opportunities Prospected 45 Opportunities Under Review 13 Active Processes Personal Care T
Slide 12: Driving Top Line Growth: How BD Heads Will Drive Growth
Driving Top Line Growth: How BD Heads Will Drive Growth We will exit July with 750 BD FTEs. As we continue to ramp BD heads with the goal of reaching a net 775 in 4Q’17, and assuming a normal productivity level, we will achieve our Episodic growth targets of 2-3% in 3Q’17 and 4-6% in 4Q’17 Quarter E
Slide 13: Debt and Liquidity Metrics
Debt and Liquidity Metrics Low debt levels (0.3x) and strong free cash flow ($34M in 2Q’17) have improved the flexibility of our balance sheet with ample available liquidity Net debt defined as total debt outstanding ($94M) less cash balance ($59M) Leverage ratio (net) is defined as net debt divided
Slide 14: Adjusted EBITDA to Free Cash Flow Reconciliation
Adjusted EBITDA to Free Cash Flow Reconciliation (1,2) Reduction in amount of non-GAAP adjustments result in adjusted EBITDA falling through to operating cash flow; looking return DSO to mid-30’s by YE’17. Capex target of $10M - $12M within projected goal for 2017 The financial results for the three
Slide 15: Income Statement Adjustments
Income Statement Adjustments (1) Amount of non-GAAP adjustments, excluding legal settlements, have substantially decreased. Trend to continue throughout 2H’17 The financial results for the three-month periods ended June 30, 2016, September 30, 2016, December 31, 2016, March 31, 2017 and June 30, 201
Slide 16: Home Health Groupings Model (HHGM)
Home Health Groupings Model (HHGM) It is still early and we lack needed data to draw firm conclusions, but here is what we know: What it is / Issues: HHGM is a total payment redesign for Home Health with the stated intent of better aligning resources and outcomes with reimbursement HHGM has an effec